Actor Patrick Dempsey is helping patients get over the pressure of scheduling an appointment
The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?
Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.
He spent more than 30 years at the pharmaceutical company.
In an unusual twist, the makers of cholesterol drug Praluent are re-pricing the treatment to align with the nonprofit's recommendation. Is industry warming to ICER?
Why the drugmaker's partnership with a YouTube star is still getting hits.
As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.
Direct-to-consumer drug marketing spend dropped most heavily in the magazine and digital categories.
Now more than ever, patients aren't shy about sharing their wants and needs. Here, 8,000 patients from three generations in the U.S., U.K., Germany, and France weigh in on everything from brand loyalty to the factors that drive their decision-making-processes to the reasons they switch treatments.
The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.
Virta Health CEO Sami Inkinen on changing patient behavior: 'We're cutting down trees in the wrong forest'
Seven questions for the Virta Health chief executive and cofounder of Trulia.
A WEGO Health white paper examined how the change could affect patient influencers.
Dohmen will continue to operate under its brand and retain its leadership team.
The agency began working with the national reproductive center this month.
There was so much bigger-picture coverage of pharma and healthcare in 2017 - pricing, Affordable Care Act reform and repeal - that it was easy to lose sight of everything else. PwC's Health Research Institute has used its annual look-ahead report to spotlight a handful of undercover trends.
As the evidence mounts that high-deductibles don't cause patients to shop or save for healthcare, payers are taking note.
Critics said the initial spots unnecessarily blamed IBD sufferers.
Allergan Q4 earnings beat estimates; Mars publishes research policies; Conway takes control of White House opioid agenda.
Opdivo hits key goal in late-stage trial; Philippines government sues Sanofi over anti-dengue vaccine; hospitals reach capacity amid record flu season.
This year, the Super Bowl and World Cancer Day fall on the same date.
The nonprofit worked with creative agency E/LA on the push.
For some pharma brands, the price tag is just too high. For others, the platform isn't serious enough.
For all the talk about new and better ways to engage, pharma still hasn't created an appreciably higher volume of satisfied — or informed — customers.
Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.
Pharmacy benefit managers are increasingly measuring a patient's outcome in the context of adherence.
Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a potent market force
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
The drugmaker eliminated its U.S. primary care, disease-focused endocrinology, and hospital chronic-care sales teams.
Two point-of-care companies have received hundreds of millions of dollars in funding. One of them, Outcome Health, is facing allegations about padding data.
Still, most experts characterize this year's newly approved women's health drugs as modest improvements rather than groundbreaking advances in medicine.
Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.
Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.
The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.
Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?
Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.
Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?
Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.
What's holding back value-based pricing deals from moving beyond the pilot phase?
The goal is to further cement point of care as a mainstream media channel.
Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.
Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.
A particular focus is put on the emerging research about cannabis and its benefits for the human body.
It's the third year of consecutive growth for spending on accredited CME, according to the Accreditation Council for Continuing Medical Education.
Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.
The deal highlights ongoing interest in the influential point-of-care market.
Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
The chip-in-a-pill combines antipsychotic Abilify with an ingestible sensor made by Proteus.
Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.
Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions
Execs stressed the importance of collaboration, consumer-mindedness.
Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.
Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.
AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.
The research found a reduction in utilization of medications used to treat depression, nausea, and psychosis when looking at data for Medicaid beneficiaries.
How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?
A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.
The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.
While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs
There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.
Pharmaceutical companies often blur the lines between a drug's risks and benefits in ads, and that frustrates physicians.
Pfizer and Bristol-Myers Squibb were the top spenders last year.
The data stems from the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.
He describes his current charge as "transforming a more creative occupation into a science."
Valeant added 250 primary care sales reps to promote its Salix portfolio.
J&J discloses list prices for its drugs; Kite's CAR-T therapy meets study goals; healthcare providers seek to engage patients in decisionmaking
Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.
When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."
Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.
Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.
Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.
If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.
The drugmaker is planning a commercial boost for its HIV-prevention drug.
Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.
Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.
WPP will create "Team WBA," a bespoke team that would work on traditional and digital advertising, media, and PR.
Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.
A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.
Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.
That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"
"In Australia, we are the healthcare industry," he says.
The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.
The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?
Find out what stories generated the most interest among our readers.
Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine
Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.
Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.
Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey
The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.
More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.
Specialty pharma ace Umer Raffat, a senior analyst at Evercore ISI, shares his 2016 postmortem and a few quick-hit predictions for 2017.
"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.
How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information
BMS and Pfizer outspent Johnson & Johnson two-to-one in advertising for their oral anticoagulant last year.
Tech companies and Bernie Sanders have found the millennial audience easy to crack. Organizations in and around healthcare? Not so much.
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.